SCHEMBL9923988

SCHEMBL9923988

O=S(=O)(c1ccc(N2CCOCC2)nc1)N(Cc1ccc(C(F)(F)F)c(F)c1)c1nc2ccccn2c1Br

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42
TRPM8 Q7Z2W7 11/20 0.41
HSD17B10 Q99714 1/20 0.40
PRKDC P78527 1/20 0.36
PIK3CA P42336 1/20 0.36
NAMPT P43490 1/20 0.36
SFRP1 Q8N474 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923989 0.94 TRPM8 (0.44) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9924009 0.91 KDM4E (0.44) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9923984 0.86 KDM4E (0.59) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9893342 0.86 TRPM8 (0.44) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9923987 0.85 TRPM8 (0.48) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9923934 0.83 TRPM8 (0.46) MEN1KMT2ATRPM8
SCHEMBL9923971 0.83 KDM4E (0.41) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9924003 0.81 KDM4E (0.41) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9924011 0.80 KDM4E (0.49) KDM4EMEN1LMNAPKMKMT2A
SCHEMBL9924012 0.80 KDM4E (0.47) KDM4EMEN1LMNAPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
WO-2012078994-A1 IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-06-14 WO disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885MEN1 1061/4885LMNA 3025/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 KDM4E 3480/4885MEN1 1061/4885LMNA 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.